Literature DB >> 35490048

A multidisciplinary approach to optimize primary prostate cancer biobanking.

Peter Y Cai1, Muhammad Asad2, Michael A Augello3, Laura Martin4, Christopher Louie2, Spyridon P Basourakos1, Christopher D Gaffney1, Jonathan Shoag5, Jiangling Jenny Tu2, Francesca Khani6, Juan Miguel Mosquera7, Massimo Loda8, Douglas S Scherr1, Christopher E Barbieri9, Brian D Robinson10.   

Abstract

PURPOSE: Biobanking tissue of high quality and fidelity is imperative for cancer genomics research. Since it is a challenging process, we sought to develop a protocol that improves the fidelity and quantity of biobanked primary prostate cancer (CaP) tissue.
MATERIALS AND METHODS: We conducted a pilot study evaluating pathologic concordance of biobanked tissue and the radical prostatectomy specimen using either standard protocol (SP) vs. next-generation protocol (NGP).
RESULTS: There were no significant differences in clinical and pathologic characteristics (age, BMI, preoperative PSA, prostate weight, race, final prostatectomy Gleason score, or pathologic tumor and nodal stages) between the two protocol arms. Utilization of the NGP compared to the standard protocol resulted in a significantly higher rate of pathologic concordance between the biobanked and RP specimens (61.8% vs. 37.9%, P = 0.0231) as well as a nearly two-fold increase in the amount of biobanked tumor tissue (330 mm3 vs. 174 mm3, P < 0.001). When looking at relevant clinical and pathologic characteristics, NGP was associated with pathologic concordance on both univariate [OR 2.65 (95% CI 1.13-6.21), P = 0.025] and multivariate analysis [OR 3.11 (95% CI 1.09-8.88), P = 0.034].
CONCLUSIONS: Our study validates the NGP as a multidisciplinary approach for improving the fidelity and amount of biobanked primary CaP tissue for future studies. Given the challenges to banking tissue from primary CaP as tumors are often difficult to visualize grossly and are frequently multifocal, optimizing the fidelity and volume of biobanked tissue is an important step forward to improve the generalizability of genomic data as we move towards precision medicine.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Biobank; Fresh frozen tissue; Gleason score; Gross pathology; Molecular subtype; Pathology; Prostate cancer; Radical prostatectomy; TCGA; Tumor volume

Mesh:

Substances:

Year:  2022        PMID: 35490048      PMCID: PMC9117451          DOI: 10.1016/j.urolonc.2022.03.015

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   2.954


  17 in total

Review 1.  International efforts to develop biospecimen best practices.

Authors:  Jimmie B Vaught; Elodie Caboux; Pierre Hainaut
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-03-16       Impact factor: 4.254

Review 2.  The potential of organoids in urological cancer research.

Authors:  Shangqian Wang; Dong Gao; Yu Chen
Journal:  Nat Rev Urol       Date:  2017-05-23       Impact factor: 14.432

3.  Next-generation prostate cancer biobanking: toward a processing protocol amenable for the International Cancer Genome Consortium.

Authors:  Raquel Esgueva; Kyung Park; Robert Kim; Naoki Kitabayashi; Christopher E Barbieri; Philip J Dorsey; Cyril Abraham; Samprit Banerjee; Robert A Leung; Ashutosh K Tewari; Stéphane Terry; Maria M Shevchuk; David S Rickman; Mark A Rubin
Journal:  Diagn Mol Pathol       Date:  2012-06

4.  Intratumoral and Intertumoral Genomic Heterogeneity of Multifocal Localized Prostate Cancer Impacts Molecular Classifications and Genomic Prognosticators.

Authors:  Lei Wei; Jianmin Wang; Erika Lampert; Simon Schlanger; Adam D DePriest; Qiang Hu; Eduardo Cortes Gomez; Mitsuko Murakam; Sean T Glenn; Jeffrey Conroy; Carl Morrison; Gissou Azabdaftari; James L Mohler; Song Liu; Hannelore V Heemers
Journal:  Eur Urol       Date:  2016-07-21       Impact factor: 20.096

5.  Organoid cultures derived from patients with advanced prostate cancer.

Authors:  Dong Gao; Ian Vela; Andrea Sboner; Phillip J Iaquinta; Wouter R Karthaus; Anuradha Gopalan; Catherine Dowling; Jackline N Wanjala; Eva A Undvall; Vivek K Arora; John Wongvipat; Myriam Kossai; Sinan Ramazanoglu; Luendreo P Barboza; Wei Di; Zhen Cao; Qi Fan Zhang; Inna Sirota; Leili Ran; Theresa Y MacDonald; Himisha Beltran; Juan-Miguel Mosquera; Karim A Touijer; Peter T Scardino; Vincent P Laudone; Kristen R Curtis; Dana E Rathkopf; Michael J Morris; Daniel C Danila; Susan F Slovin; Stephen B Solomon; James A Eastham; Ping Chi; Brett Carver; Mark A Rubin; Howard I Scher; Hans Clevers; Charles L Sawyers; Yu Chen
Journal:  Cell       Date:  2014-09-04       Impact factor: 41.582

6.  Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate.

Authors:  Rebecca Arora; Michael O Koch; John N Eble; Thomas M Ulbright; Lang Li; Liang Cheng
Journal:  Cancer       Date:  2004-06-01       Impact factor: 6.860

7.  Integrative clinical genomics of advanced prostate cancer.

Authors:  Dan Robinson; Eliezer M Van Allen; Yi-Mi Wu; Nikolaus Schultz; Robert J Lonigro; Juan-Miguel Mosquera; Bruce Montgomery; Mary-Ellen Taplin; Colin C Pritchard; Gerhardt Attard; Himisha Beltran; Wassim Abida; Robert K Bradley; Jake Vinson; Xuhong Cao; Pankaj Vats; Lakshmi P Kunju; Maha Hussain; Felix Y Feng; Scott A Tomlins; Kathleen A Cooney; David C Smith; Christine Brennan; Javed Siddiqui; Rohit Mehra; Yu Chen; Dana E Rathkopf; Michael J Morris; Stephen B Solomon; Jeremy C Durack; Victor E Reuter; Anuradha Gopalan; Jianjiong Gao; Massimo Loda; Rosina T Lis; Michaela Bowden; Stephen P Balk; Glenn Gaviola; Carrie Sougnez; Manaswi Gupta; Evan Y Yu; Elahe A Mostaghel; Heather H Cheng; Hyojeong Mulcahy; Lawrence D True; Stephen R Plymate; Heidi Dvinge; Roberta Ferraldeschi; Penny Flohr; Susana Miranda; Zafeiris Zafeiriou; Nina Tunariu; Joaquin Mateo; Raquel Perez-Lopez; Francesca Demichelis; Brian D Robinson; Marc Schiffman; David M Nanus; Scott T Tagawa; Alexandros Sigaras; Kenneth W Eng; Olivier Elemento; Andrea Sboner; Elisabeth I Heath; Howard I Scher; Kenneth J Pienta; Philip Kantoff; Johann S de Bono; Mark A Rubin; Peter S Nelson; Levi A Garraway; Charles L Sawyers; Arul M Chinnaiyan
Journal:  Cell       Date:  2015-05-21       Impact factor: 41.582

8.  Biobanking after robotic-assisted radical prostatectomy: a quality assessment of providing prostate tissue for RNA studies.

Authors:  Harveer Dev; David Rickman; Prasanna Sooriakumaran; Abhishek Srivastava; Sonal Grover; Robert Leung; Robert Kim; Naoki Kitabayashi; Raquel Esqueva; Kyung Park; Jessica Padilla; Mark Rubin; Ashutosh Tewari
Journal:  J Transl Med       Date:  2011-07-26       Impact factor: 5.531

9.  Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.

Authors:  Himisha Beltran; Davide Prandi; Juan Miguel Mosquera; Matteo Benelli; Loredana Puca; Joanna Cyrta; Clarisse Marotz; Eugenia Giannopoulou; Balabhadrapatruni V S K Chakravarthi; Sooryanarayana Varambally; Scott A Tomlins; David M Nanus; Scott T Tagawa; Eliezer M Van Allen; Olivier Elemento; Andrea Sboner; Levi A Garraway; Mark A Rubin; Francesca Demichelis
Journal:  Nat Med       Date:  2016-02-08       Impact factor: 53.440

10.  Patient derived organoids to model rare prostate cancer phenotypes.

Authors:  Loredana Puca; Rohan Bareja; Davide Prandi; Reid Shaw; Matteo Benelli; Wouter R Karthaus; Judy Hess; Michael Sigouros; Adam Donoghue; Myriam Kossai; Dong Gao; Joanna Cyrta; Verena Sailer; Aram Vosoughi; Chantal Pauli; Yelena Churakova; Cynthia Cheung; Lesa Dayal Deonarine; Terra J McNary; Rachele Rosati; Scott T Tagawa; David M Nanus; Juan Miguel Mosquera; Charles L Sawyers; Yu Chen; Giorgio Inghirami; Rema A Rao; Carla Grandori; Olivier Elemento; Andrea Sboner; Francesca Demichelis; Mark A Rubin; Himisha Beltran
Journal:  Nat Commun       Date:  2018-06-19       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.